Investors of REGENXBIO Inc. Urged to Join Securities Fraud Lawsuit

REGENXBIO Inc. Securities Fraud Lawsuit

In a significant legal move, the Schall Law Firm, a prominent national shareholder rights litigation firm, has notified investors of a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX). This legal action arises due to alleged violations pertaining to §10(b) and §20(a) of the Securities Exchange Act of 1934 as well as SEC Rule 10b-5. The law firm encourages all individuals who purchased securities of REGENXBIO between February 9, 2022 and January 27, 2026, inclusive, to reach out for potential involvement in the lawsuit.

The Context of the Lawsuit

REGENXBIO specializes in gene therapies for various diseases, and its product candidate, RGX-111, generated substantial interest from investors. However, the firm’s optimism was overshadowed by concerns surrounding misleading statements made by the company regarding the safety and efficacy of RGX-111. Specifically, the complaint alleges that while REGENXBIO promoted denoted positive outcomes for RGX-111, critical safety data indicating a serious adverse effect remained undisclosed.

During a trial phase, a participant was found to have developed an intraventricular CNS tumor after receiving RGX-111. This alarming revelation prompted the firm’s claims that REGENXBIO’s public statements were misleading and inconsistent with the actual risks associated with its therapies. The class action targets these misrepresentations that led investors to sustain financial losses when the truth about the product came to light.

Investor Participation

The law firm underscores the importance for affected investors to act promptly. Those who suffered damages due to a decline in the value of their REGENXBIO investments during the specified period are encouraged to contact them before the deadline on April 14, 2026, to ensure their rights are protected.

Interested shareholders can reach out to Brian Schall at the Schall Law Firm located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. Individuals can also connect through their website, or call 310-301-3335 for a complimentary consultation regarding their rights as investors.

Conclusion

As the landscape of investment litigation evolves, the REGENXBIO case serves as a cautionary tale about the critical nature of transparency and honesty in the market. The Schall Law Firm remains committed to representing the rights of shareholders and comprehensively addressing allegations of securities fraud. By joining this class action, investors can take a stand and recover potential losses incurred during a period marked by misleading information.

For more information on this case and to explore participation opportunities, visit the Schall Law Firm’s website or contact them directly. Remember, if no action is taken, investors may remain classified as absent class members, forfeiting any potential recourse available.

This message is brought to you by the Schall Law Firm, underscoring their dedication to investor rights and advocacy.